Physician profile
Gary M Freeman
NPI 1114906732
$14,938.45
in general payments reported to CMS, 2019-2025
65 companies · $2,393 in 2025
The $2,393 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,709 · 2020: $1,331 · 2021: $2,218 · 2022: $2,772 · 2023: $2,229 · 2024: $2,286 · 2025: $2,393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,837 · Education: $71.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,837.40 |
| Education | $71.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,831.74 | 2019-2025 | |
| Novo Nordisk INC | $1,656.80 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,206.68 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $1,044.32 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $883.62 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $693.25 | 2019-2025 | |
| Abbott Laboratories | $682.93 | 2019-2025 | Freestyle Libre 3 |
| Amgen INC. | $645.63 | 2019-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $598.48 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Bayer Healthcare Pharmaceuticals INC. | $560.79 | 2021-2025 | |
| Amarin Pharma, INC. | $469.22 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $395.69 | 2022-2025 | Rexulti, Nuedexta |
| Merck Sharp & Dohme LLC | $369.51 | 2019-2025 | Gardasil 9, Vaxelis, Capvaxive |
| Sanofi-Aventis U.S. LLC | $281.19 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $272.90 | 2019-2024 | Livalo, Seglentis |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.